The rights bring TYRVAYA's approvals, intellectual property, inventory, and contracts outside Japan into Harrow's business. That expands its dry-eye treatment business and adds possible Japan royalties, though cash paid and future sales-based payments temper the benefit.
This gives Harrow the product approvals, intellectual property, inventory, and contracts outside Japan. Viatris also owes Harrow royalties on Japanese sales. Harrow used cash on hand and may owe more if sales targets are met. Those costs temper the benefit, but the acquired rights broaden its dry-eye treatment business.
Viatris received $30 million and may receive up to $70 million more if sales targets are met. It gave up TYRVAYA rights outside Japan and owes Harrow royalties on Japanese sales, so the deal's gains and costs point in different directions.
Follow Harrow, Inc. (HROW) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for HROW